RAGE
RAGE Molecule Information
Name:Advanced glycosylation end product-specific receptor
Target Synonym:RAGE;AGER;Advanced glycosylation end product-specific receptor;Receptor for advanced glycosylation end products
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Phase ?
RAGE Molecule Synonym Name
AGER,RAGE
RAGE Molecule Background
Advanced glycosylation end product-specific receptor (AGER) is also known as RAGE, and is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. AGER is highly expressed in endothelial cells. AGER mediates interactions of advanced glycosylation end products (AGE), and also accumulates in vascular tissue in aging and at an accelerated rate in diabetes, as well as acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGER / RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes.
RAGE References
RAGE Related Molecule
RAGE Clinical Drug Information
Name |
Research Code |
Research Phase |
Company |
Indications |
Clinical Trials |
Azeliragon |
TTP-488; PF-04494700; PF-4494700,PF04494700,TTP488 |
Phase Ⅲ |
vTv Therapeutics |
Alzheimer's disease (AD) |
Details
|
Tenilsetam |
CAS-997 |
Phase Not Specified |
Sanofi |
Dementia |
Details
|
TRC-041266 |
TRC-041266 |
Phase Ⅲ |
Torrent Pharmaceuticals |
Chronic heart failure |
Details
|
TRC-4186 |
TX-41XX; TRC-4186 |
Phase Ⅱ |
Torrent Pharmaceuticals |
Diabetic complications, Heart failure |
Details
|
Alagebrium chloride |
ALT-711 |
Phase Ⅲ |
Synvista Therapeutics |
Cardiovascular disorders, Erectile dysfunction (ED), Hypertension, Heart failure |
Details
|
TTP-4000 |
TTP-4000 |
Phase Ⅰ |
vTv Therapeutics |
Alzheimer's disease (AD) |
Details
|